Revenue on track, profit delayed — overhead absorption masks the Q1 story

Amanta's Q1 result splits into two stories. Revenue grew at the guided pace (+5.4% YoY), and EBITDA margin sat at 21.8% — a hair below 22% prior-year levels. But profits collapsed: PAT fell 5.6% YoY despite revenue growth, net margin compressed to 4.8%, and the company missed the 24–25% EBITDA margin guidance it reiterated on prior calls. The tension is real, but not mysterious. Management's delay of SteriPort Line 3 from Q1 to Q2 forced pre-commissioning overhead absorption into Q1 without offsetting revenue. Polymer costs spiked and were only 67% recovered via price increases. Depreciation and interest rose on new capex. None of this contradicts the long-term thesis — but it means near-term earnings disappointment is not a one-quarter blip.

The real story: SteriPort Line 3 was originally targeted for Q1 commissioning but slipped 4–5 months due to civil construction delays. As a result, manpower hired for the new facility incurred costs in Q1 without contributing revenue. Additionally, polymer raw material spiked 70–80% over ~2 months; Amanta passed through ₹1.50 per unit of the ₹2.25 per unit impact (67% recovery), absorbing the ₹0.75 per unit shortfall. Depreciation and interest expense rose from new capex (solar, SVP prep). The company did not withdraw or materially downgrade FY27–28 guidance — it acknowledged the timing slip and outlined a recovery path: SteriPort Line 3 commissioning late August, baseline revenue ₹370 Cr from existing portfolio, expansion contribution ₹70 Cr over 7 months = ~₹440 Cr FY27 revenue. FY28 peak: ₹425 Cr at 25–26% EBITDA margins once all facilities (SteriPort Line 3, SVP, solar) hit run-rate.

The stock closed at ₹150.01 ahead of the result, +63% off its 52-week low and −8.53% from its all-time high of ₹164. Price momentum is bullish: RSI 60.9 (neutral, not overbought), volume increasing, and the stock trades above all key moving averages (SMA20, SMA50). This positioning suggests the market has factored in some near-term weakness but retains conviction in the long-term story. However, institutional flows tell a different tale: FII ownership declined 25 basis points QoQ (0.85% in Q4 vs. 1.10% in Q3), trimming exposure even as the stock rallied. DII ownership rose 164 basis points QoQ (12.88% vs. 11.24%), indicating domestic institutions are adding. Block/bulk deals over the past 6 months show institutional churn around the ₹156–₹159 price range (near ATH), with sell volume outweighing buy volume by notional value — a sign that tactical profit-taking is occurring at highs. The market's posture is cautiously optimistic: the long-term case (₹425 Cr FY28, 25–26% EBITDA) is accepted, but near-term execution stumbles (margin miss, overhead absorption) are being punished with selective selling at peaks. Holders are not panic-selling; instead, they are waiting for Q2 evidence that margins recover as expected.